Mona S. El Ashry

Mona S. El Ashry

Auto-generated profile, based on publicly available information

Mona S. El Ashry

Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Open access
PDF file
NSNevine Fawzy Shafik
Nevine Fawzy Shafik
MAMona S. El Ashry
Mona S. El Ashry
RBRagia H. Badawy
Ragia H. Badawy
MHMarwa M. Hussein
Marwa M. Hussein
NHNaglaa M. Hassan
Naglaa M. Hassan
The aim of this work is to investigate the different expression patterns of B cell-specifics moloney murine Leukemia virus integration site-1 (BMI-1) and brain and acute leukemia, cytoplasmic (BAALC) genes, their prognostic and clinical significance in newly diagnosed cytogenetically heterogenous adult acute myeloid leukemia patients. BMI-1 and BAALC expression was detected in the bone marrow of patients using quantitative real-time reverse transcription polymerase chain reaction with cut off value set at 50th percentile for both genes. BMI-1 and BAALC overexpression was detected in 50% of cases which suggest their potential as molecular markers. A statistical significant correlation was found between BMI-1 expression with hepatomegaly (P value = 0.007), hemoglobin level-grouped (P value = 0.047) and cytogenetic risk groups (P value = 0.036). There was a statistically significant correlation between BAALC and age (P value = 0.015), lymphadenopathy (P value = 0.043), CD34 expression (P value = 0.003) and near statistical significance with FAB sub-groups (P value = 0.054). No statistical significance was noted for other hematological findings and response to treatment except for BAALC gene and treatment response (P value = 0.014). No statistical significance in overall survival and disease free survival for both genes was found. Their prospective screening in combination with other molecular markers can help refine myeloid leukemia staging and prognosis toward optimizing therapeutic interventions.

25 June 2026 in Journal of Hematopathology
Verified
Journal Article
Closed access
HNHend A. Nooh
Hend A. Nooh
RARasha M. Abdel-Hamid
Rasha M. Abdel-Hamid
MAMona S. Abdellateif
Mona S. Abdellateif
LRLobna Refaat
Lobna Refaat
ABAhmed Bayoumi
Ahmed Bayoumi
MEMona S. ElAshry
Mona S. ElAshry